Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 70.38 Thousand CHF | -19.13% |
| 2022 | 87.02 Thousand CHF | -55.21% |
| 2021 | 194.31 Thousand CHF | -24.91% |
| 2020 | 258.78 Thousand CHF | 46.02% |
| 2019 | 177.22 Thousand CHF | 0.0% |
| 2018 | - CHF | 0.0% |
| 2017 | - CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| 2012 | - CHF | 0.0% |
| 2011 | - CHF | 0.0% |
| 2010 | - CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 0.0% |
| 2007 | - CHF | 0.0% |
| 2006 | - CHF | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 19.79 Thousand CHF | 0.0% |
| 2024 Q1 | 22.94 Thousand CHF | 0.0% |
| 2023 Q3 | 116.9 Thousand CHF | 258.21% |
| 2023 Q4 | 70.38 Thousand CHF | -39.8% |
| 2023 FY | 70.38 Thousand CHF | -19.13% |
| 2023 Q2 | 32.63 Thousand CHF | -10.18% |
| 2023 Q1 | 36.33 Thousand CHF | -58.25% |
| 2022 FY | 87.02 Thousand CHF | -55.21% |
| 2022 Q4 | 87.02 Thousand CHF | -46.01% |
| 2022 Q3 | 161.18 Thousand CHF | 71.16% |
| 2022 Q1 | 120.76 Thousand CHF | -37.85% |
| 2022 Q2 | 94.16 Thousand CHF | -22.02% |
| 2021 Q2 | 161.48 Thousand CHF | -13.69% |
| 2021 FY | 194.31 Thousand CHF | -24.91% |
| 2021 Q1 | 187.11 Thousand CHF | -27.7% |
| 2021 Q4 | 194.31 Thousand CHF | -15.6% |
| 2021 Q3 | 230.23 Thousand CHF | 42.57% |
| 2020 FY | 258.78 Thousand CHF | 46.02% |
| 2020 Q1 | 103.65 Thousand CHF | -41.51% |
| 2020 Q3 | 53.68 Thousand CHF | -28.03% |
| 2020 Q4 | 258.78 Thousand CHF | 382.04% |
| 2020 Q2 | 74.58 Thousand CHF | -28.04% |
| 2019 Q1 | - CHF | 0.0% |
| 2019 Q2 | 114.01 Thousand CHF | 0.0% |
| 2019 Q4 | 177.22 Thousand CHF | 0.0% |
| 2019 FY | 177.22 Thousand CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 FY | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2017 FY | - CHF | 0.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2017 Q1 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 Q3 | - CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2014 Q3 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2013 Q1 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 0.0% |
| 2012 Q4 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2012 FY | - CHF | 0.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 FY | - CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2010 Q2 | - CHF | 0.0% |
| 2010 Q4 | - CHF | 0.0% |
| 2010 FY | - CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 0.0% |
| 2007 FY | - CHF | 0.0% |
| 2006 FY | - CHF | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BB Biotech AG | 304.9 Million CHF | 99.977% |
| Basilea Pharmaceutica AG | 95.45 Million CHF | 99.926% |
| Evolva Holding SA | - CHF | -Infinity% |
| Idorsia Ltd | 931 Million CHF | 99.992% |
| Kuros Biosciences AG | 1.56 Million CHF | 95.503% |
| Molecular Partners AG | 2.44 Million CHF | 97.12% |
| Relief Therapeutics Holding AG | 9000.00 CHF | -682.0% |
| Santhera Pharmaceuticals Holding AG | 1.47 Million CHF | 95.238% |